Description
EXARIO CEF-325 is a combination antibiotic formulation containing Cefixime (200mg), a third-generation cephalosporin, and Clavulanic Acid (125mg), a beta-lactamase inhibitor. This dual-action combination enhances the effectiveness of Cefixime against a wide range of bacteria, including those that produce beta-lactamase enzymes, which can make bacteria resistant to standard antibiotics.
Cefixime (200mg): Cefixime is a broad-spectrum antibiotic that works by disrupting the synthesis of the bacterial cell wall, ultimately leading to bacterial death. It is effective against both gram-positive and gram-negative bacteria and is commonly used for treating respiratory tract infections, urinary tract infections, and gastrointestinal infections.
Clavulanic Acid (125mg): Clavulanic Acid is a beta-lactamase inhibitor that protects Cefixime from being broken down by beta-lactamase enzymes produced by certain resistant bacteria. This allows Cefixime to remain active and effective against a broader range of pathogens, particularly those resistant to other antibiotics.
EXARIO CEF-325 is indicated for treating bacterial infections such as acute otitis media, sinusitis, bronchitis, pneumonia, urinary tract infections, and skin and soft tissue infections. The combination of Cefixime and Clavulanic Acid offers a more comprehensive approach to treating infections caused by both sensitive and resistant bacteria.
